Butyric monosaccharide ester-induced cell differentiation and anti-tumor activity in mice. Importance of their prolonged biological effect for clinical applications in cancer therapy - PubMed (original) (raw)
. 1991 Aug 19;49(1):89-95.
doi: 10.1002/ijc.2910490117.
Affiliations
- PMID: 1874576
- DOI: 10.1002/ijc.2910490117
Butyric monosaccharide ester-induced cell differentiation and anti-tumor activity in mice. Importance of their prolonged biological effect for clinical applications in cancer therapy
P Pouillart et al. Int J Cancer. 1991.
Abstract
The interest of butyric salts is based on their capacity to promote differentiation of malignant cells and inhibition of tumor development. The phenotypic modifications are rapidly reversible and require the continuous presence of butyric salts in the target area, which raises problems for therapeutic applications. We show here that the covalent binding of n-butyric acid on natural polyhydroxylated compounds such as monosaccharides, especially 3- or 6-O-butanoyl-1,2-O-isopropylidene-alpha-D-glucofuranose, retains the majority of the biological properties of n-butyric acid. The delayed degradation of these covalent compounds is associated with an improved maintenance of cell differentiation and anti-tumor protection in mice. These butyric complexes thus seem potentially useful for therapeutic applications.
Similar articles
- [Protective activity of monoacetone glucose 3-butyrate, prodrug of n-butyric acid, against the fatal effect of encephalomyocarditis virus in mice].
Pouillart P, Cerutti I, Ronco G, Villa P, Chany C. Pouillart P, et al. C R Acad Sci III. 1992;314(2):49-54. C R Acad Sci III. 1992. PMID: 1313734 French. - Novel anticancer prodrugs of butyric acid. 2.
Nudelman A, Ruse M, Aviram A, Rabizadeh E, Shaklai M, Zimrah Y, Rephaeli A. Nudelman A, et al. J Med Chem. 1992 Feb 21;35(4):687-94. doi: 10.1021/jm00082a009. J Med Chem. 1992. PMID: 1542095 - Derivatives of butyric acid as potential anti-neoplastic agents.
Rephaeli A, Rabizadeh E, Aviram A, Shaklai M, Ruse M, Nudelman A. Rephaeli A, et al. Int J Cancer. 1991 Aug 19;49(1):66-72. doi: 10.1002/ijc.2910490113. Int J Cancer. 1991. PMID: 1874573 - A phase I study of pivaloyloxymethyl butyrate, a prodrug of the differentiating agent butyric acid, in patients with advanced solid malignancies.
Patnaik A, Rowinsky EK, Villalona MA, Hammond LA, Britten CD, Siu LL, Goetz A, Felton SA, Burton S, Valone FH, Eckhardt SG. Patnaik A, et al. Clin Cancer Res. 2002 Jul;8(7):2142-8. Clin Cancer Res. 2002. PMID: 12114414 Review. - Role of butyric acid and its derivatives in the treatment of colorectal cancer and hemoglobinopathies.
Pouillart PR. Pouillart PR. Life Sci. 1998;63(20):1739-60. doi: 10.1016/s0024-3205(98)00279-3. Life Sci. 1998. PMID: 9820119 Review.
Cited by
- Copper-catalyzed synthesis of pyrazolo[1,5-a]pyrimidine based triazole-linked glycohybrids: mechanistic insights and bio-applications.
Tiwari G, Khanna A, Tyagi R, Mishra VK, Narayana C, Sagar R. Tiwari G, et al. Sci Rep. 2024 Jan 4;14(1):529. doi: 10.1038/s41598-023-50202-4. Sci Rep. 2024. PMID: 38177184 Free PMC article. - Synthesis, characterization, antibacterial and antifungal evaluation of novel monosaccharide esters.
Shen Y, Sun Y, Sang Z, Sun C, Dai Y, Deng Y. Shen Y, et al. Molecules. 2012 Jul 23;17(7):8661-73. doi: 10.3390/molecules17078661. Molecules. 2012. PMID: 22825619 Free PMC article. - Butyrate affects differentiation, maturation and function of human monocyte-derived dendritic cells and macrophages.
Millard AL, Mertes PM, Ittelet D, Villard F, Jeannesson P, Bernard J. Millard AL, et al. Clin Exp Immunol. 2002 Nov;130(2):245-55. doi: 10.1046/j.0009-9104.2002.01977.x. Clin Exp Immunol. 2002. PMID: 12390312 Free PMC article. - Identification and comparative analysis of human colonocyte short-chain fatty acid response genes.
Basson MD, Liu YW, Hanly AM, Emenaker NJ, Shenoy SG, Gould Rothberg BE. Basson MD, et al. J Gastrointest Surg. 2000 Sep-Oct;4(5):501-12. doi: 10.1016/s1091-255x(00)80093-1. J Gastrointest Surg. 2000. PMID: 11077326 - A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors.
Saito A, Yamashita T, Mariko Y, Nosaka Y, Tsuchiya K, Ando T, Suzuki T, Tsuruo T, Nakanishi O. Saito A, et al. Proc Natl Acad Sci U S A. 1999 Apr 13;96(8):4592-7. doi: 10.1073/pnas.96.8.4592. Proc Natl Acad Sci U S A. 1999. PMID: 10200307 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources